Proud to see our project published in @ClinicalLung Germline Mutation Analysis and Real-World Impact in a Selected Cohort of Patients with Non-Small Cell Lung Cancer: INHERITY LC study https://t.co/W4zrZBggc1 Thanks to @Icapem_vida,@Maria_Zurera_, and the rest of the authors

Interest in focal approaches such as stereotactic radiosurgery (SRS) is growing for brain metastases in small-cell lung cancer (SCLC). A new systematic review explores this evolving field. Link: https://t.co/xZjLX49391

Pulmonary sarcomatoid carcinomas are rare and aggressive tumors, often exhibiting limited response to chemotherapy. In a phase II study (n=20), #durvalumab combined with doxorubicin and ifosfamide achieved a 35% objective response rate. https://t.co/0jH0GMaHop

Report on neratinib-based trials in HER2 mutant NSCLC @ClinicalLung show minimal activity. In PUMA-NER-4201 study (n=60), RR 0% with neratinib +/- trastuzumab. In SUMMIT trial, neratinib monotherapy RR 3.8%. Fortunate to have more novel TKIs now. https://t.co/JsDSY5qY4W

Thank you @StephenVLiu for sharing our recent case series highlighting a rare, but potentially serious AE (tumor lysis syndrome) with tarlatamab in #SCLC in @ClinicalLung. @IUCancerCenter @OhioState @AsrarAlahmadi @oncodaily @OncoAlert @LungCancerRx

Case series of tumor lysis syndrome with the bispecific T-cell engager tarlatamab in patients with small cell lung cancer @ClinicalLung. I have not seen this myself, but for various reasons, tarlatamab in #SCLC could be better with lower disease burden. https://t.co/lpMRTUnTX1

CNS outcomes with lazertinib for #EGFR mutant NSCLC @ClinicalLung. In 64 pts with no prior treatment (24 measurable), intracranial PFS 27.7m, intracranial RR 92%, intracranial DOR 26.5m. Common related AEs: paresthesia (47%), rash (41%), pruritus (36%). https://t.co/PArmu5M59M

Our work looking at segmentectomy in #SCLC : comparable outcomes to lobectomy in early stage tumors found at resection 🫁 @ClinicalLung @okusanyamd @ResearchAtJeff @JEFFsurgery https://t.co/0QE60BmW26

Small cell lung cancer is not typically a surgical disease - but in cases where a true stage I SCLC is identified, segmentectomy may be as appropriate as lobectomy. In this report @ClinicalLung, no difference in nodal upstaging or survival. https://t.co/awbDpg5Ulq

Retrospective analysis @ClinicalLung looks at maintenance immunotherapy vs maintenance chemo + IO and shows similar PFS (16.1m, 11.5m). Agree that IO is the more important piece but caution here with lots of selection bias in this real world report. https://t.co/izC9T1pWbs

How common is rebiopsy after progression on targeted therapy for NSCLC? Report @ClinicalLung included 148 pts with EGFR, ALK, and ROS1 NSCLC post TKI and 53% had rebiopsy - 47% tissue, 33% liquid, 20% both. Biopsy gave new information for 40% of pts. https://t.co/wmoBit4XxE

In a single-center study of NSCLC resections (2008-2020), long-term postop mortality dropped by almost 50% (HR 0.59; 95% CI 0.45–0.78) over 12 years, despite stable early post-op complications, possibly reflecting multiple contributing factors Read more: https://t.co/61CqiEGWbZ

Durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: outcomes in age, sex, and platinum subgroups from the phase 3 CASPIAN study - @ClinicalLung

Subgroup analyses from CASPIAN (1L platinum + etoposide + durvalumab for ES-SCLC) reported @ClinicalLung. Addition of durva to chemotherapy improved outcomes across subgroups - cisplatin vs carboplatin, sex, and age. No PRO detriment by age. https://t.co/pU9ZJTGR6G

HIgher rwOS in #Patients w/ #EGFR mutated #NSCLC & #germline #BRCA or #PALB2 PGVs vs #patients w/o #BRCA/#PALB2 Possibly 2/2 enhanced response to platinum based chemotherapy ...opens the question for whether #universal #germlinetesting is appropriate in #patients w/...#NSCLC.

Real world outcomes in #BRAF NSCLC reported @ClinicalLung. 1L dabrafenib + trametinib RR 67%, PFS 13.1m compared to chemotherapy RR 39%, PFS 6.1m. D+T performed similarly across lines. Question remains: targeted vs immunotherapy first? I prefer targeted. https://t.co/U3QZppCs9X

#ALK is a viable target even in squamous NSCLC, demonstrated by this case + review in @ClinicalLung. However, significant variability in quality of response. While most respond, many brief courses of crizotinib, one on 1L alectinib for 5y and counting. https://t.co/us1ycJkdHo

Retrospective report of durvalumab in pts with unresectable stage III NSCLC after chemoradiation @ClinicalLung. Compared to historic cohort, OS better with durvalumab across PD-L1 strata, including PD-L1 negative, though outcomes better with PD-L1+. https://t.co/v85KqoP2XU

3y f/u from Italian Phase IIIB MAURIS trial @ClinicalLung - 1L carboplatin + etoposide + atezolizumab in a broader, real-world population. 1y OS rate 45.5%, 2y OS rate 31.0%, 3y OS rate 14.5%, mOS 10.6m, mPFS 5.5m. https://t.co/4v9s2xgIFS

Outcomes Following 1L Immune Checkpoint Inhibitors +/- Chemo Stratified by KRAS Mutational Status -- Real-World Analysis in Pts w/ Advanced NSCLC [May 28, 2025] Cantor et al @CharuAggarwalMD @ClinicalLung https://t.co/s27F7cLi0O #lcsm #ImmunoOnc #PrecisionMedicine @TempusAI